Q-omics provides the consensus-scored SNORA46 profile across patient tissues and cancer cell-line models. SNORA46 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, SNORA46 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, SNORA46 RNA expression shows 9,997 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where SNORA46 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORA46 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORA46 survival associations across molecular data types. SNORA46 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORA46 RNA expression–survival associations across cancer types. High SNORA46 expression shows unfavorable associations in KICH, ACC, CESC, DLBC, PCPG and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for SNORA46 RNA expression.
This table summarizes SNORA46 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORA46. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORA46 shows lower tumor expression in THCA, KICH and COAD and higher tumor expression in HNSC, LUSC and COAD. The HNSC box plot shows higher SNORA46 RNA expression in tumor versus normal tissue (log2 FC = +0.742, t-test p = .013).
This table shows molecular features associated with SNORA46 in patient tissues and cancer cell lines. In patient samples, SNORA46 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
